Targeting the NRF2 pathway: A promising approach for corneal endothelial dysfunction
Curr Opin Pharmacol. 2024 Jan 2;74:102429. doi: 10.1016/j.coph.2023.102429. Online ahead of print.ABSTRACTMaintaining corneal endothelial function is required for vision, and corneal endothelial dysfunction is a major cause of visual deficits and blindness worldwide. To date there has been a dearth of innovation for therapeutics targeting the corneal endothelium. However, recent advances in understanding the role of oxidative stress and mitochondrial dysfunction have revealed potential avenues for the development of new therapies. This review summarizes recent developments in elucidating the role of the NRF2 pathway in cor...
Source: Current Opinion in Pharmacology - January 3, 2024 Category: Drugs & Pharmacology Authors: Keith W Ward Source Type: research
Optic nerve regeneration: Potential treatment approaches
Curr Opin Pharmacol. 2024 Jan 2;74:102428. doi: 10.1016/j.coph.2023.102428. Online ahead of print.ABSTRACTThe optic nerve, predominantly constituted by the axons of retinal ganglion cells (RGCs), lacks the ability to regenerate and re-establish function after injury. RGCs are crucial for visual function, and thus, RGC death contributes to the development of numerous progressive neurodegenerative optic neuropathies including glaucoma, ischemic optic neuropathy, and optic neuritis. Regenerating optic nerve axons poses numerous challenges due to factors such as the intricate and inhibitory conditions that exist within their e...
Source: Current Opinion in Pharmacology - January 3, 2024 Category: Drugs & Pharmacology Authors: Jessica Lee Sherilyn Nguyen Sanjoy Bhattacharya Source Type: research
Human experience and efficacy of omidenepag isopropyl (Eybelis ®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug
Curr Opin Pharmacol. 2024 Jan 1;74:102426. doi: 10.1016/j.coph.2023.102426. Online ahead of print.ABSTRACTMore than 75 million people worldwide suffer from ocular hypertension (OHT)-associated retinal and optic nerve degenerative diseases that cause visual impairment and can lead to blindness. In an effort to find novel pharmaceutical therapeutics to combat OHT with reduced side-effect potential, several emerging drug candidates have advanced to human proof-of-concept in recent years. One such compound is a nonprostaglandin (non-PG) EP2-receptor-selective agonist (omidenepag isopropyl ester). Omidenepag (OMD; free acid for...
Source: Current Opinion in Pharmacology - January 3, 2024 Category: Drugs & Pharmacology Authors: Najam A Sharif Source Type: research
Targeting the NRF2 pathway: A promising approach for corneal endothelial dysfunction
Curr Opin Pharmacol. 2024 Jan 2;74:102429. doi: 10.1016/j.coph.2023.102429. Online ahead of print.ABSTRACTMaintaining corneal endothelial function is required for vision, and corneal endothelial dysfunction is a major cause of visual deficits and blindness worldwide. To date there has been a dearth of innovation for therapeutics targeting the corneal endothelium. However, recent advances in understanding the role of oxidative stress and mitochondrial dysfunction have revealed potential avenues for the development of new therapies. This review summarizes recent developments in elucidating the role of the NRF2 pathway in cor...
Source: Current Opinion in Pharmacology - January 3, 2024 Category: Drugs & Pharmacology Authors: Keith W Ward Source Type: research
Optic nerve regeneration: Potential treatment approaches
Curr Opin Pharmacol. 2024 Jan 2;74:102428. doi: 10.1016/j.coph.2023.102428. Online ahead of print.ABSTRACTThe optic nerve, predominantly constituted by the axons of retinal ganglion cells (RGCs), lacks the ability to regenerate and re-establish function after injury. RGCs are crucial for visual function, and thus, RGC death contributes to the development of numerous progressive neurodegenerative optic neuropathies including glaucoma, ischemic optic neuropathy, and optic neuritis. Regenerating optic nerve axons poses numerous challenges due to factors such as the intricate and inhibitory conditions that exist within their e...
Source: Current Opinion in Pharmacology - January 3, 2024 Category: Drugs & Pharmacology Authors: Jessica Lee Sherilyn Nguyen Sanjoy Bhattacharya Source Type: research
Human experience and efficacy of omidenepag isopropyl (Eybelis ®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug
Curr Opin Pharmacol. 2024 Jan 1;74:102426. doi: 10.1016/j.coph.2023.102426. Online ahead of print.ABSTRACTMore than 75 million people worldwide suffer from ocular hypertension (OHT)-associated retinal and optic nerve degenerative diseases that cause visual impairment and can lead to blindness. In an effort to find novel pharmaceutical therapeutics to combat OHT with reduced side-effect potential, several emerging drug candidates have advanced to human proof-of-concept in recent years. One such compound is a nonprostaglandin (non-PG) EP2-receptor-selective agonist (omidenepag isopropyl ester). Omidenepag (OMD; free acid for...
Source: Current Opinion in Pharmacology - January 3, 2024 Category: Drugs & Pharmacology Authors: Najam A Sharif Source Type: research
Targeting the NRF2 pathway: A promising approach for corneal endothelial dysfunction
Curr Opin Pharmacol. 2024 Jan 2;74:102429. doi: 10.1016/j.coph.2023.102429. Online ahead of print.ABSTRACTMaintaining corneal endothelial function is required for vision, and corneal endothelial dysfunction is a major cause of visual deficits and blindness worldwide. To date there has been a dearth of innovation for therapeutics targeting the corneal endothelium. However, recent advances in understanding the role of oxidative stress and mitochondrial dysfunction have revealed potential avenues for the development of new therapies. This review summarizes recent developments in elucidating the role of the NRF2 pathway in cor...
Source: Current Opinion in Pharmacology - January 3, 2024 Category: Drugs & Pharmacology Authors: Keith W Ward Source Type: research
Optic nerve regeneration: Potential treatment approaches
Curr Opin Pharmacol. 2024 Jan 2;74:102428. doi: 10.1016/j.coph.2023.102428. Online ahead of print.ABSTRACTThe optic nerve, predominantly constituted by the axons of retinal ganglion cells (RGCs), lacks the ability to regenerate and re-establish function after injury. RGCs are crucial for visual function, and thus, RGC death contributes to the development of numerous progressive neurodegenerative optic neuropathies including glaucoma, ischemic optic neuropathy, and optic neuritis. Regenerating optic nerve axons poses numerous challenges due to factors such as the intricate and inhibitory conditions that exist within their e...
Source: Current Opinion in Pharmacology - January 3, 2024 Category: Drugs & Pharmacology Authors: Jessica Lee Sherilyn Nguyen Sanjoy Bhattacharya Source Type: research
Currently available prostanoids for the treatment of glaucoma and ocular hypertension: A review
This article offers a comprehensive review of available prostanoid analogs and explores new developments.PMID:38160646 | DOI:10.1016/j.coph.2023.102424 (Source: Current Opinion in Pharmacology)
Source: Current Opinion in Pharmacology - December 31, 2023 Category: Drugs & Pharmacology Authors: Betsy Benitez Abdelrahman M Anter Jennifer Arcuri Sanjoy K Bhattacharya Source Type: research
Currently available prostanoids for the treatment of glaucoma and ocular hypertension: A review
This article offers a comprehensive review of available prostanoid analogs and explores new developments.PMID:38160646 | DOI:10.1016/j.coph.2023.102424 (Source: Current Opinion in Pharmacology)
Source: Current Opinion in Pharmacology - December 31, 2023 Category: Drugs & Pharmacology Authors: Betsy Benitez Abdelrahman M Anter Jennifer Arcuri Sanjoy K Bhattacharya Source Type: research
Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation
Curr Opin Pharmacol. 2023 Dec;73:102415. doi: 10.1016/j.coph.2023.102415. Epub 2023 Dec 1.ABSTRACTTranslating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT2) receptor is a clinically-validated target based upon positive proof-of-concept clinical trial data in patients with post-herpetic neuralgia. This trial was conducted because AT2 receptor antagonists evoked pain relief in rodent models of neuropathic pain. EMA401 was selected as the drug candidate based upon its suitable preclinical toxicity and safety pro...
Source: Current Opinion in Pharmacology - December 2, 2023 Category: Drugs & Pharmacology Authors: Andrew J Shepherd Andrew Sc Rice Maree T Smith Source Type: research
Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation
Curr Opin Pharmacol. 2023 Dec;73:102415. doi: 10.1016/j.coph.2023.102415. Epub 2023 Dec 1.ABSTRACTTranslating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT2) receptor is a clinically-validated target based upon positive proof-of-concept clinical trial data in patients with post-herpetic neuralgia. This trial was conducted because AT2 receptor antagonists evoked pain relief in rodent models of neuropathic pain. EMA401 was selected as the drug candidate based upon its suitable preclinical toxicity and safety pro...
Source: Current Opinion in Pharmacology - December 2, 2023 Category: Drugs & Pharmacology Authors: Andrew J Shepherd Andrew Sc Rice Maree T Smith Source Type: research
Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation
Curr Opin Pharmacol. 2023 Dec;73:102415. doi: 10.1016/j.coph.2023.102415. Epub 2023 Dec 1.ABSTRACTTranslating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT2) receptor is a clinically-validated target based upon positive proof-of-concept clinical trial data in patients with post-herpetic neuralgia. This trial was conducted because AT2 receptor antagonists evoked pain relief in rodent models of neuropathic pain. EMA401 was selected as the drug candidate based upon its suitable preclinical toxicity and safety pro...
Source: Current Opinion in Pharmacology - December 2, 2023 Category: Drugs & Pharmacology Authors: Andrew J Shepherd Andrew Sc Rice Maree T Smith Source Type: research
Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation
Curr Opin Pharmacol. 2023 Dec;73:102415. doi: 10.1016/j.coph.2023.102415. Epub 2023 Dec 1.ABSTRACTTranslating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT2) receptor is a clinically-validated target based upon positive proof-of-concept clinical trial data in patients with post-herpetic neuralgia. This trial was conducted because AT2 receptor antagonists evoked pain relief in rodent models of neuropathic pain. EMA401 was selected as the drug candidate based upon its suitable preclinical toxicity and safety pro...
Source: Current Opinion in Pharmacology - December 2, 2023 Category: Drugs & Pharmacology Authors: Andrew J Shepherd Andrew Sc Rice Maree T Smith Source Type: research
Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation
Curr Opin Pharmacol. 2023 Dec;73:102415. doi: 10.1016/j.coph.2023.102415. Epub 2023 Dec 1.ABSTRACTTranslating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT2) receptor is a clinically-validated target based upon positive proof-of-concept clinical trial data in patients with post-herpetic neuralgia. This trial was conducted because AT2 receptor antagonists evoked pain relief in rodent models of neuropathic pain. EMA401 was selected as the drug candidate based upon its suitable preclinical toxicity and safety pro...
Source: Current Opinion in Pharmacology - December 2, 2023 Category: Drugs & Pharmacology Authors: Andrew J Shepherd Andrew Sc Rice Maree T Smith Source Type: research
